Coronavirus disease 2019 (COVID-19) increases the risk of thromboembolic events,
especially in patients with severe infections requiring intensive care and cardiorespiratory …

Background The novel coronavirus SARS-CoV-2, responsible for the 2019–2020 global
(COVID-19) pandemic, is a respiratory virus associated with the development of …

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is associated with
high risk of venous and arterial thrombosis. Thrombotic complications, especially pulmonary …

Abstract Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by
the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite …

Emerging evidences prove that the ongoing pandemic of coronavirus disease 2019 (COVID-
19) is strictly linked to coagulopathy even if pneumonia appears as the major clinical …

Abstract Severe coronavirus (COVID-19) infection has been reportedly associated with a
high risk of thromboembolism. Developing macrovascular thrombotic complications …

Emerging evidence shows that the recent pandemic of coronavirus disease 19 (COVID-19)
is characterized by coagulation activation and endothelial dysfunction. This increases the …

There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a
significant coagulopathy, a phenomenon termed “COVID-19 associated coagulopathy.” …

COVID‐19 (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) is associated
with coagulopathy through numerous mechanisms. The reported incidence of venous …

The novel coronavirus disease (COVID-19) is associated with a high incidence of
coagulopathy and venous thromboembolism that may contribute to the worsening of the …